Enfusion

Geographic Expansion And New Products Will Strengthen Market Position

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

15 Sep 24

Updated

17 Apr 25

n/a

AnalystConsensusTarget's Fair Value

n/a

15.1%

-1.5%

15.1%

-1.5%

You can edit this narrative until May 12 6:01 AM. Then, changes will post as Updates.

Author's Valuation

US$15.2529.4% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates6

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 2.97%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 11 Mar 25

Fair value Decreased 5.25%

AnalystConsensusTarget has decreased profit margin from 19.6% to 13.2% and increased future PE multiple from 31.4x to 46.2x.

AnalystConsensusTarget Fair Value

US$15.25

29.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

14.66%

Software revenue growth rate

1.24%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.62%

Calculation

US$41.36m

Earnings '28

47.80x

PE Ratio '28

US$1.98b

Market Cap '28

US$1.98b

Market Cap '28

104.03m

No. shares '28

US$19.01

Share Price '28

US$19.01 Share Price '28

Discounted to 2025 @ 7.62% p.a.

US$15.25

Fair Value '25